Patent application number | Description | Published |
20090155827 | PIGF and FLT-1 as Prognostic Parameters for Cardiovascular Diseases - The present invention refers to a use of an ex vivo method comprising the determination of PlGF and sFlt-1 in a sample for diagnosis, risk stratification and/or monitoring of a vascular disease with atherosclerotic etiology, in particular a coronary heart disease such a unstable angina pectoris or myocardial infarction, and/or for estimation of the probability of developing such a disease, as well as for identification of a patient supposed to benefit from a therapy by agents reducing the risk for a cardiovascular disease. In the method (i) a ratio of [PlGF=high:sFlt-1=low], and/or (ii) a PlGF concentration in the upper two tertiles of a reference collective, and an sFlt-1 concentration in the lower tertile of the reference collective, and/or (iii) a PlGF result above a PlGF reference value, and an sFlt-1 result below an sFlt-1-reference value indicate an elevated probability for an adverse event. The present invention also refers to the used method. The present invention further refers to a diagnostic kit and its use as well as to an assay element and its use. | 06-18-2009 |
20100324118 | Method for the Promotion of Angiogenesis, Vascularization, or Vascular Repair or for the Inhibition of Tumor Angiogenesis - The invention relates to a method for influencing the miR-92 expression in a cell, comprising the following steps: (a) providing a cell; and (b1) reducing the miR-92 expression in the cell in order to promote the vascularization or vessel repair by introducing an antisense molecule against miR-92 into the cell, or (b2) increasing the miR-92 expression in the cell for an inhibition of the tumor angiogenesis by introducing a construct into the cell, wherein said construct includes an expressible miR-92 sequence. Furthermore, the invention relates to a pharmaceutical composition, comprising an agent for reducing the miR-92 activity or expression in a cell in the form of an antisense molecule against miR-92, or an agent for increasing the miR-92 expression in a cell in the form of a construct for expressing miR-92. | 12-23-2010 |
20120238619 | MICRO-RNA FOR THE REGULATION OF CARDIAC APOPTOSIS AND CONTRACTILE FUNCTION - The present invention relates to treating or preventing age-related cardiomyopathy by modulating the expression or activity of a miR-34 family member and/or PNUTS. Methods of treating or preventing age-related cardiomyopathy include administering an inhibitor of miR-34 expression or activity or an agonist of PNUTS expression or activity. Also provided herein are methods of treating or preventing cardiac fibrosis and myocardial infarction by administering an inhibitor of miR-34 expression or activity or an agonist of PNUTS expression or activity. | 09-20-2012 |
20120322856 | Method for Promoting Angiogenesis, Vascularization, or Vessel Repair or for the Inhibiting Tumor Angiogenesis - The invention relates to a method for influencing the miR-92 expression in a cell, comprising the following steps: (a) providing a cell; and (b1) reducing the miR-92 expression in the cell in order to promote the vascularization or vessel repair by introducing an antisense molecule against miR-92 into the cell, or (b2) increasing the miR-92 expression in the cell for an inhibition of the tumor angiogenesis by introducing a construct into the cell, wherein said construct includes an expressible miR-92 sequence. Furthermore, the invention relates to a pharmaceutical composition, comprising an agent for reducing the miR-92 activity or expression in a cell in the form of an antisense molecule against miR-92, or an agent for increasing the miR-92 expression in a cell in the form of a construct for expressing miR-92. | 12-20-2012 |
20150018407 | METHOD FOR PROMOTING ANGIOGENESIS, VASCULARIZATION OR VESSEL REPAIR OR FOR INHIBITING TUMOR ANGIOGENESIS - The invention relates to a method for influencing the miR-92 expression in a cell, comprising the following steps: (a) providing a cell; and (b1) reducing the miR-92 expression in the cell in order to promote the vascularization or vessel repair by introducing an antisense molecule against miR-92 into the cell, or (b2) increasing the miR-92 expression in the cell for an inhibition of the tumor angiogenesis by introducing a construct into the cell, wherein said construct includes an expressible miR-92 sequence. Furthermore, the invention relates to a pharmaceutical composition, comprising an agent for reducing the miR-92 activity or expression in a cell in the form of an antisense molecule against miR-92, or an agent for increasing the miR-92 expression in a cell in the form of a construct for expressing miR-92. | 01-15-2015 |
Patent application number | Description | Published |
20110218294 | BLENDS OF POLYARYLENE ETHERS AND POLYARYLENE SULFIDES - The present invention relates to thermoplastic molding compositions comprising the following components:
| 09-08-2011 |
20110237693 | Blends made of polyarylene ethers and of polyarylene sulfides - The present invention relates to thermoplastic molding compositions comprising the following components:
| 09-29-2011 |
20110251337 | BLENDS OF POLYARYLENE ETHERS AND POLYARYLENE SULFIDES COMPRISING CARBOXYLIC ANHYDRIDES - The present invention relates to compositions comprising the following components:
| 10-13-2011 |
20110318524 | METHOD FOR PRODUCING A COMPOSITE COMPONENT BY MULTI-COMPONENT INJECTION MOLDING - The invention relates to processes for the production of a composite component via multicomponent injection molding, where the composite component comprises a main body composed of a thermoplastic A) and an external layer composed of a foamed thermoplastic B), where the main body is produced in a first process step a) via injection molding of the thermoplastic A) and subsequent hardening of the same in an injection mold, and an external layer is injected on to the main body in a second process step b) which follows directly, via injection molding of a mixture comprising the thermoplastic B) and comprising a chemical blowing agent, and the mixture is subsequently hardened in the same injection mold, with somewhat extended cavity, and the external layer injected on to the main body is foamed in a further process step d) via introduction of heat, and the composite component is solidified via cooling in a final process step e), where an essential feature of the invention is that it comprises using, as thermoplastic B) in the mixture used in process step b), at least one polyamide whose modulus of elasticity derived from the tensile test (tensile modulus) E | 12-29-2011 |
20120252962 | BLENDS OF POLYARYLENE ETHERS AND POLYARYLENE SULFIDES - The present invention relates to thermoplastic molding materials comprising the following components:
| 10-04-2012 |
20120296031 | BLENDS OF POLYARYLENE ETHERS AND POLYARYLENE SULFIDES - The present invention relates to thermoplastic molding materials comprising the following components:
| 11-22-2012 |